We value your feedback, take our 2025 surveyhere

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Don't want ads? Click here
Sponsored Content
Don't want ads? Click here

Pin to quick picksIQ-AI Share News (IQAI)

Share Price Information for IQ-AI (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.825
Bid: 0.80
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.05 (6.25%)
Open: 0.825
High: 0.825
Low: 0.825
Prev. Close: 0.825
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Timelines are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Airtel And Telkom Abort Kenya Combination

Wed, 05th Aug 2020 22:03

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Airtel Africa PLC - Africa-focused mobile operator - Subsidiary Airtel Networks Kenya Ltd and Telkom Kenya Ltd business combination in Kenya falls through after "a very lengthy process which has led the parties to reconsider their stance". The two businesses are no longer pursuing completion of the combination.

----------

Adamas Finance Asia Ltd - pan-Asian diversified investment vehicle - Says Future Metal Holdings Ltd asset quarry set to operate at full production for the rest of 2020 after a temporary pause in early 2020 amid the Covid-19 pandemic. Quarry operations in Future Metal's open-pit dolomite quarry in Shanxi Province, China resumed in mid-March. Adamas says that, given the "continuing rapid urbanisation" in China, demand for Future Metal's product is likely to say "robust".

----------

Regency Mines PLC - battery metals company - Proposes name change to Corcel PLC with the aim of more closely reflecting its "strategy to develop its businesses across the battery metals exploration and flexible grid solutions space." Application for name change being made to Companies House and a new website it to be launched.

----------

TP Group PLC - Reading-based software solutions provider - Subsidiary Sapienza Consulting chosen to participate in framework contract providing consulting and technical services for Eurocontrol. Framework to last up to five years and relates to "Common IT Contractor Profiles at the Maastricht Upper Area Control Centre (MUAC) in the Netherlands." Eurocontrol to release restricted tenders to pre-qualified participants for "a range of specialist capabilities" under this framework. Eurocontrol described by TP as "a pan-European civil-military organisation dedicated to supporting European aviation".

----------

MediaZest PLC - London-based audio visual services provider - Raises GBP150,000 through issue of unsecured convertible loan notes with maturity date August 2023. Proceeds will provide more working capital for MediaZest and have interest of 7% per annum. Chief Executive Geoff Robertson: "We are delighted to announce the fundraise at a difficult time for all businesses and we're grateful for the continuing support of shareholders as we move out of the UK lockdown period and seek to build on the group's encouraging performance in the run up to the Covid-19 outbreak."

----------

Hummingbird Resources PLC - African gold producer - Provides second quarter operational and trading update on Yanfolila showing 24,054 ounces gold poured in period, down from 27,466 ounces in the same quarter of 2019. Sells 31,520 ounces of gold at USD1,663 average price per ounce. All in sustaining cost for Yanfolila USD963 per ounce versus USD998 year-on-year. Recordable injury frequency rate 2.3, under 2.5 target. June 30 cash USD6 million versus USD9 million December 31 and 4,000 ounces gold inventory on hand compared to 2.900 ounced 2019 end worth around USD8 million. Reduces bank debt by USD14 million from December to USD26 million. Maintains 2020 guidance for 11,000 to 125,000 ounces and ASIC USD995 per ounce. On track for net cash position target in second half with bank loans repaid by end of 2021 first half. Q2 Yanfolila mine drill intersections received includes 5.7 metres at 16.42 grams per tonne of ore from 263 metres depth.

----------

IQ-AI Ltd - medical software company with headquarters in Jersey - Signs letter of intent with undisclosed "major international medical group" that wishes to buy StoneChecker Software Ltd. The sale is part of IQ-AI's decision to focus on neuro imaging. StoneChecker analyses CT assets the evaluate the likelihood of a kidney stone breaking up when a patient undergoes lithotripsy, where shock waves are used to break up kidney stones. This procedure fails 29% of the time and StoneChecker would therefore reduce the the number of these failed procedures. If completed, the sales will involve a cash consideration as well as ongoing royalty on sales.

----------

Cora Gold Ltd - West African focused gold company - Says warrant holders have exercised their right to subscribe for 55,564 depositary interests at 10 pence each, raising GBP55,556 in total.

----------

NB Global Floating Rate Income Fund Ltd - closed-ended investment company incorporated in Guernsey - Intends to propose investment policy amendment and institure new discount control mechanism. This includes a revised investment objective letting it invest in a broader range of assets such as alternative credit. It will also pay income on a monthly basis starting from the declaration of its third quarter dividend. It explains: "The new investment objective will mean the trust can still invest in 'senior secured, floating rate' loans where the majority of its portfolio is currently held, but will also be able to invest in a broad range of other debt types." New proposals will involve a tender offer to let shareholder exist the trust, which is trading on an 8% discount, at a 2% discount. The discount control policy will let investors tender shares at a 3% discount every six months.

----------

Tiziana Life Sciences PLC - London-headquartered biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases - Closes American Depositary Shares registered direct offering. Issues 11.0 million ADSs as USD5.20 each raising USD57.25 million gross. ThinkEquity, division of Fordham Financial Management Inc, is sole placement agenct. Proceeds will help advance clinical development of Foralumab and allow it to start a trial in HCC patients with Milciclib. Funds also assist in expediating clinical development of TZLS-501 for Covid-19.

----------

Columbus Energy Resources PLC - oil and gas producer and explorer focused on onshore Trinidad and Suriname - Gets court sanction for scheme to effect merger with Bahamas Petroleum Co PLC, expected to be effective August 7. August 6 to be last day of dealings in Columbus shares.

----------

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
2 May 2025 13:28

IN BRIEF: IQ-AI applies for breakthrough therapy designation for GaM

IQ-AI Ltd - London-based medical services company - Says subsidiary Imaging Biometrics LLC has applied for breakthrough therapy designation from the US Food & Drug Administration for its oral gallium maltolate therapy. Its phase 1 trial is evaluating the therapy as a potential treatment for adult patients with recurrent or refractory glioblastoma IDH-wildtype, with preliminary findings suggesting an overall survival of 34.1 months from initial diagnosis. This significantly exceeds the median survival of 14 to 15 months reported for patients undergoing standard treatment, though IQ-AI notes that caution is appropriate when considering the results due to the size of the trial population. The FDA is required to respond to IQ-AI's application within 60 days.

Read more
3 Feb 2025 19:22

IN BRIEF: IQ-AI amends distribution deal with Blackford Analysis

IQ-AI Ltd - London-based medical services company - Amends existing distribution agreement with artificial intelligence platform provider Blackford Analysis Ltd. The amendment adds IB Nimble, IB ASL, IB FTB, and IB FTB Express to the agreement, allowing Blackford to also sell these products to their global client base. Acquired by Bayer in early 2023, Blackford operates in the healthcare AI platform and solutions sphere.

Read more
22 Jan 2025 17:10

IN BRIEF: IQ-AI to take GaM to phase II study, flags AI capabilities

IQ-AI Ltd - London-based medical services company - Provides operations update focusing on artificial intelligence. Explains radiology leads the way in Food & Drug Administration approvals for AI-enabled products as the FDA has increased efforts to keep pace with the advancements in AI technology. The company believes its subsidiary, Imaging Biometrics LLC, is in a unique position to lead this transformation for neuro-oncology in 2025 and beyond. Points to the imminent release of the new version of IB Clinic; its FDA-cleared suite of quantitative imaging solutions will include the incorporation of an AI model, which will greatly improve diagnostic accuracy and speed. In addition, notes the first half of 2025 should mark the next release of IB Nimble with the functionality to view IB's AI-generated images and other images within the mobile app. Also, in 2025 we anticipate releasing a new product leveraging arterial spin labelling.

Read more
14 Oct 2024 10:05

IN BRIEF: Braveheart buys 30% stake in IQ-AI from Braveheart CEO Brown

IQ-AI Ltd - parent of Wisconsin-based Imaging Biometrics LLC, which provides quantitative imaging platforms and therapeutics for the diagnosis and treatment of patients - AIM-listed technology investor Braveheart Investment Group PLC buys a nearly 30% stake in IQ-AI from Braveheart Chief Executive Officer Trevor Brown. Braveheart buys 45.8 million IQ-AI shares from Brown at 1.1 pence per share, worth GBP503,372, and another 19.7 million shares owned by Brown's children at the same price, worth GBP216,203. The two purchases give Braveheart a 29.5% stake in IQ-AI. Braveheart on Friday says the related-party transaction is approved by its independent shareholders because the IQ-AI business fits Braveheart's investment strategy and the purchase is at "an attractive entry price".

Read more
16 Aug 2024 20:40

TRADING UPDATES: NetScientific loss narrows; Vinanz ups Bitcoin fleet

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and Wednesday and not separately reported by Alliance News:

Read more
25 Jun 2024 11:56

IN BRIEF: IQ-AI subsidiary opens expanded access programme

IQ-AI Ltd - London-based medical services company - US-based subsidiary Imaging Biometrics LLC says that US Food & Drug Administration has approved an expanded access programme for oral gallium maltolate. This EAP will run in parallel with the current phase 1 clinical trial being conducted at the Medical College of Wisconsin. Explains that "As the phase 1 trial concludes this fall and while the data is being compiled, eligible patients in the US will have the option of participating in the EAP."

Read more
14 Jun 2024 14:32

IQ-AI team begins defining phase 2 protocol for oral gallium maltolate

(Alliance News) - IQ-AI Ltd on Friday said the clinical team has started a phase 2 protocol for its oncology-focused drug oral gallium maltolate, which could be a therapeutic agent for cancer.

Read more
23 May 2024 21:08

TRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pact

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
20 May 2024 11:16

IQ-AI subsidiary gets second FDA rare paediatric disease designation

(Alliance News) - IQ-AI Ltd on Monday said its subsidiary, Imaging Biometrics LLC, received a second rare paediatric disease designation by the US Food & Drug Administration for its IB-003 lead drug candidate oral gallium maltolate.

Read more
17 May 2024 17:39

TRADING UPDATES: Ingenta trades in line; Triple Point Social NAV up

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
10 May 2024 15:14

IQ-AI subsidiary gets rare paediatric disease designation FDA

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary, Imaging Biometrics LLC, has been granted rare paediatric disease designation by the US Food & Drug Administration for its lead drug candidate, IB-003, or gallium maltolate for the treatment of ATRT.

Read more
2 May 2024 15:45

EARNINGS AND TRADING: Trident Royalties swings to profit

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
22 Feb 2024 14:02

IN BRIEF: IQ-AI shares sink on discounted placing fundraise

IQ-AI Ltd - Medical services firm and parent company of Wisconsin-based healthcare imaging software firm Imaging Biometrics LLC - Announces placing to raise GBP300,000 gross proceeds via the issue of 20.0 million new shares at a price of 1.5p each. The issue price represents a discount of 32% to the company's Wednesday closing price of 2.2p. The placing includes a broker option for existing shareholders for up to 6.7 million new shares, which would raise an additional GBP100,000. Admission of the new placing and broker option shares is expected to occur on or around March 1.

Read more
9 Feb 2024 13:38

IQ-AI subsidiary asked by FDA to resubmit and modify application

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary Imaging Biometric LLC will modify and resubmit its application to the US Food & Drug Administration.

Read more
2 Feb 2024 08:56

IN BRIEF: IQ-AI celebrates USD100,000 grant for subsidiary

IQ-AI Ltd - St Helier, Jersey-based medical services firm - Says that Imaging Biometrics LLC, a wholly-owned subsidiary of IQ-AI, has been given a USD100,000 grant by the Musella Foundation For Brain Tumor Research & Information Inc. Explains that the grant will help to support the launch of an intermediate group expanded access programme, which is focused on giving brain tumour patients access to oral gallium maltolate, outside of an ongoing Phase One clinical trial at the Medical College of Wisconsin. The grant will be used to facilitate the expanded access programme, including writing and submitting the study protocol, patient screening and on-boarding.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.